Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M, Gavin A, Visser O, Bray F. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018;103:356–87. https://doi.org/10.1016/j.ejca.2018.07.005.
Article
CAS
PubMed
Google Scholar
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.
Article
PubMed
Google Scholar
Walters S, Maringe C, Butler J, Rachet B, Barrett-Lee P, Bergh J, et al. Breast cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK, 2000-2007: a population-based study. Br J Cancer. 2013;108(5):1195–208. https://doi.org/10.1038/bjc.2013.6.
Article
CAS
PubMed
PubMed Central
Google Scholar
Reinert T, Barrios CH. Optimal management of hormone receptor positive metastatic breast cancer in 2016. Ther Adv Med Oncol. 2015;7(6):304–20.
Article
CAS
PubMed
PubMed Central
Google Scholar
Lobbezoo DJ, van Kampen RJ, Voogd AC, Wouter Dercksen M, van den Berkmortel F, Smilde TJ, et al. Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2- positive subtype is associated with the most favourable outcome. Breast Cancer Res Treat. 2013;141(3):507–14.
Article
CAS
PubMed
Google Scholar
Başaran GA, Twelves C, Diéras V, Cortes J, Awada A. Ongoing unmet needs in treating estrogen receptor-positive/HER2-negative metastatic breast cancer. Cancer Treat Rev. 2018;63:144–55.
Article
PubMed
Google Scholar
Gong Y, Liu YR, Ji P, Hu X, Shao ZM. Impact of molecular subtypes on metastatic breast cancer patients: a SEER population-based study. Sci Rep. 2017;7:45411. https://doi.org/10.1038/srep45411.
Article
CAS
PubMed
PubMed Central
Google Scholar
Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, André F, et al. 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4). Ann Oncol. 2018;29(8):1634–57. https://doi.org/10.1093/annonc/mdy192.
Article
CAS
PubMed
Google Scholar
Reed E, Kossler I, Hawthorn J. Quality of life assessments in advanced breast cancer: should there be more consistency? Eur J Cancer Care (Engl). 2012;21(5):565–80.
Article
CAS
Google Scholar
Ghislain I, Zikos E, Coens C, Quinten C, Balta V, Tryfonidis K, et al. Health-related quality of life in locally advanced and metastatic breast cancer: methodological and clinical issues in randomised controlled trials. Lancet Oncol. 2016 Jul;17(7):e294–304. https://doi.org/10.1016/S1470-2045(16)30099-7.
Article
PubMed
Google Scholar
Pe M, Dorme L, Coens C, Basch E, Calvert M, Campbell A, et al. Statistical analysis of patient-reported outcome data in randomised controlled trials of locally advanced and metastatic breast cancer: a systematic review. Lancet Oncol. 2018;19(9):e459–69. https://doi.org/10.1016/S1470-2045(18)30418-2.
Article
PubMed
Google Scholar
Cleeland CS, Mayer M, Dreyer NA, Yim YM, Yu E, Su Z, et al. Impact of symptom burden on work-related abilities in patients with locally recurrent or metastatic breast cancer: Results from a substudy of the VIRGO observational cohort study. Breast. 2014;23(6):763–9.
Article
PubMed
Google Scholar
Gupta S, Zhang J, Jerusalem G. The association of chemotherapy versus hormonal therapy and health outcomes among patients with hormone receptor-positive, HER2-negative metastatic breast cancer: Experience from the patient perspective. Expert Rev Pharmacoecon Outcomes Res. 2014;14(6):929–40.
Article
PubMed
Google Scholar
Wood R, Mitra D, de Courcy J, Iyer S. Patient-reported pain severity, pain interference and health status in HR+/HER2- advanced/metastatic breast cancer. ESMO Open. 2017;2:e000227. https://doi.org/10.1136/esmoopen-2017-000227.
Article
PubMed
PubMed Central
Google Scholar
Wood R, Mitra D, de Courcy J, Iyer S. Patient-reported quality of life and treatment satisfaction in patients with HR+/HER2- advanced/metastatic breast cancer. Clin Ther. 2017;39(8):1719–28.
Article
PubMed
Google Scholar
Lambert-Obry V, Gouault-Laliberté A, Castonguay A, Zanotti G, Tran T, Mates M, et al. Real-world patient- and caregiver-reported outcomes in advanced breast cancer. Curr Oncol. 2018;25(4):e282–90.
Article
CAS
PubMed
PubMed Central
Google Scholar
DeLaurentiis M, Davis KL, Ajmera M, Mitra D, Nuzzo CMA, Harbeck N. Health-related quality of life in women with HR+/HER2- advanced or metastatic breast cancer treated in real world settings in Italy and Germany. Poster presented at ESMO 43rd Congress Oct 22, 2018.
Caldeira R, Scazafave M. Real-world treatment patterns for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in Europe and the United States. Oncol Ther. 2016;4:189–97.
Article
PubMed
Google Scholar
Anderson P, Benford M, Harris N, Karavali M, Piercy J. Real-world physician and patient behaviour across countries: Disease-Specific Programmes - a means to understand. Curr Med Res Opin. 2008;24(11):3063–72.
Article
CAS
PubMed
Google Scholar
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–76.
Article
CAS
PubMed
Google Scholar
Sprangers MA, Groenvold M, Arraras JI, Franklin J, te Velde A, Muller M, et al. The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. J Clin Oncol. 1996;14(10):2756–68.
Article
CAS
PubMed
Google Scholar
Fayers P, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A. EORTC QLQ-C30 scoring manual. 3rd ed. Brussels: European Organisation for Research and Treatment of Cancer; 2001.
Google Scholar
Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001;33(5):337–43.
Article
CAS
PubMed
Google Scholar
Szende A, Oppe M, Devlin N, editors. EQ-5D value sets: inventory, comparative review and user guide. Dordrecht: Springer Netherlands; 2007.
Google Scholar
Cleeland CS, Ryan KM. Pain assessment: global use of the brief pain inventory. Ann Acad Med Singap. 1994;23(2):129–38.
CAS
PubMed
Google Scholar
Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353–65.
Article
CAS
PubMed
Google Scholar
Serlin RC, Mendoza TR, Nakamura Y, Edwards KR, Cleeland CS. When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain. 1995;61:277–84.
Article
CAS
PubMed
Google Scholar
Cleeland CS, Body J-J, Stopeck A, von Moos R, Fallowfield L, Mathias SD, et al. Pain outcomes in patients with advanced breast cancer and bone metastases. Cancer. 2013;119:832–8.
Article
CAS
PubMed
Google Scholar
Shi Q, Mendoza TR, Dueck AC, Ma H, Zhang J, Qian Y, Bhowmik D, Cleeland CS. Determination of mild, moderate, and severe pain interference in patients with cancer. Pain. 2017;158(6):1108–12. https://doi.org/10.1097/j.pain.0000000000000890.
Article
PubMed
Google Scholar
Huber PJ. The behavior of maximum likelihood estimates under nonstandard conditions. Proceedings of the Fifth Berkeley Symposium on Mathematical Statistics and Probability, Volume 1: Statistics, 221–233. Berkeley: University of California Press; 1967.
Google Scholar
White H. A heteroskedasticity-consistent covariance matrix estimator and a direct test for heteroskedasticity. Econometrica. 1980;48:817–38.
Article
Google Scholar
White H. Maximum likelihood estimation of misspecified models. Econometrica. 1982;50:1–25.
Article
Google Scholar
European Pharmaceutical Market Research Association (EphMRA) code of conduct. Updated January 2017. http://www.ephmra.org/Code-of-Conduct-Support. Accessed 14 Nov 2018.
ICC/ESOMAR. International code on market and social research 2007. https://www.esomar.org/uploads/public/knowledge-and-standards/codes-and-guidelines/ICCESOMAR_Code_English_.pdf. Accessed 6 Feb 2018.
Scott NW, Fayers PM, Aaronson NK, Bottomley A, de Graeff A, Groenvold M, et al. EORTC QLQ-C30 reference values. Brussels: European Organisation for Research and treatment of Cancer; 2008.
Google Scholar
Hinz A, Singer S, Brähler E. European reference values for the quality of life questionnaire EORTC QLQ-C30: Results of a German investigation and a summarizing analysis of six European general population normative studies. Acta Oncol. 2014;53:958–65.
Article
PubMed
Google Scholar
Pérol D, Robain M, Arveux P, Mathoulin-Pélissier S, Chamorey E, Asselain B, et al. The ongoing French metastatic breast cancer (MBC) cohort: the example-based methodology of the Epidemiological Strategy and Medical Economics (ESME). BMJ Open. 2019;9(2):e023568. https://doi.org/10.1136/bmjopen-2018-023568.
Article
PubMed
PubMed Central
Google Scholar
Narod SA, Iqbal J, Miller AB. Why have breast cancer mortality rates declined? J Cancer Policy. 2015;5:8–17.
Article
Google Scholar
Ayyagari R, Tang D, Patterson-Lomba O, Zhou Z, Xie J, Chandiwana D, Dalal AA, Niravath PA. Progression-free survival with first-line endocrine-based therapies among postmenopausal women with HR+/HER2- metastatic breast cancer: A network meta-analysis. Clin Ther. 2018;40(4):628–39.e3. https://doi.org/10.1016/j.clinthera.2018.03.004.
Article
PubMed
Google Scholar
Kokkonen K, Saarto T, Makinen T, et al. The functional capacity and quality of life of women with advanced breast cancer. Breast Cancer. 2017;24(1):128–36.
Article
CAS
PubMed
Google Scholar
Rautalin M, Färkkilä N, Sintonen H, Saarto T, Taari K, Jahkola T, Roine RP. Health-related quality of life in different states of breast cancer - comparing different instruments. Acta Oncol. 2018;57(5):622–8. https://doi.org/10.1080/0284186X.2017.1400683.
Article
PubMed
Google Scholar
Wallwiener M, Simoes E, Sokolov AN, Brucker SY, Fasching PA, Graf J. Health-related quality of life in metastatic and adjuvant breast cancer patients. Geburtshilfe Frauenheilkd. 2016;76(10):1065–73.
Article
CAS
PubMed
PubMed Central
Google Scholar
Mosher CE, Johnson C, Dickler M, Norton L, Massie MJ, DuHamel K. Living with metastatic breast cancer: a qualitative analysis of physical, psychological, and social sequelae. Breast J. 2013;19(3):285–92. https://doi.org/10.1111/tbj.12107.
Article
PubMed
PubMed Central
Google Scholar
Galipeau N, Klooster B, Krohe M, Tang DH, Revicki DA, Cella D. Understanding key symptoms, side effects, and impacts of HR+/HER2- advanced breast cancer: qualitative study findings. J Patient Rep Outcomes. 2019 Feb 7;3(1):10. https://doi.org/10.1186/s41687-019-0098-1.
Article
PubMed
PubMed Central
Google Scholar
Costa WA, Monteiro MN, Queiroz JF, Goncalves AK. Pain and quality of life in breast cancer patients. Clinics (Sao Paulo). 2017;72(12):758–63.
Article
Google Scholar
Hollen PJ, Msaouel P, Gralla RJ. Determining issues of importance for the evaluation of quality of life and patient-reported outcomes in breast cancer: results of a survey of 1072 patients. Breast Cancer Res Treat. 2015;151(3):679–86.
Article
PubMed
Google Scholar
Wu Q, Li J, Zhu S, Wu J, Chen C, Liu Q, Wei W, Zhang Y, Sun S. Breast cancer subtypes predict the preferential site of distant metastases: a SEER based study. Oncotarget. 2017;8(17):27990–6. https://doi.org/10.18632/oncotarget.15856.
Article
PubMed
PubMed Central
Google Scholar
von Moos R, Body JJ, Rider A, de Courcy J, Bhowmik D, Gatta F, Hechmati G, Qian Y. Bone-targeted agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer in real-world practice in six European countries. J Bone Oncol. 2018;11:1–9.
Article
Google Scholar
Di Leo A, O'Shaughnessy J, Sledge GW Jr, et al. Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy. NPJ Breast Cancer. 2018;4:41. https://doi.org/10.1038/s41523-018-0094-2 eCollection 2018.
Article
CAS
PubMed
PubMed Central
Google Scholar
Maissenhaelter BE, Woolmore AL, Schlag PM. Real-world evidence research based on big data: Motivation-challenges-success factors. Onkologe (Berl). 2018;24(Suppl 2):91–8.
Article
Google Scholar
Turner-Bowker DM, Hao Y, Foley C, Galipeau N, Mazar I, Krohe M, et al. The use of patient-reported outcomes in advanced breast cancer trials: a review of the published literature. Curr Med Res Opin. 2016;32(10):1709–17.
Article
PubMed
Google Scholar
Giesinger JM, Loth FLC, Aaronson NK, Arraras JI, Caocci G, Efficace F, Groenvold M, van Leeuwen M, Petersen MA, Ramage J, Tomaszewski KA, Young T, Holzner B. EORTC Quality of Life Group. Thresholds for clinical importance were established to improve interpretation of the EORTC QLQ-C30 in clinical practice and research. J Clin Epidemiol. 2020;118:1–8.
Article
PubMed
Google Scholar
Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998;16:139–44.
Article
CAS
PubMed
Google Scholar
Cocks K, King MT, Velikova G, de Castro G Jr, Martyn St-James M, Fayers PM, Brown JM. Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. Eur J Cancer. 2012;48:1713–21.
Article
CAS
PubMed
Google Scholar
Verma S, O'Shaughnessy J, Burris HA, Campone M, Alba E, Chandiwana D, Dalal AA, Sutradhar S, Monaco M, Janni W. Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2. Breast Cancer Res Treat. 2018;170:535–45.
Article
CAS
PubMed
PubMed Central
Google Scholar
Musoro JZ, Coens C, Fiteni F, et al. Minimally important differences for interpreting EORTC QLQ-C30 scores in patients with advanced breast cancer. JNCI Cancer Spectrum. 2019;3:pkz037. https://doi.org/10.1093/jncics/pkz037.
Article
PubMed
PubMed Central
Google Scholar
Kaufman PA, Toi M, Neven P, Sohn J, Grischke EM, Andre V, Stoffregen C, Shekarriz S, Price GL, Carter GC, Sledge GW Jr. Health-related quality of life in MONARCH 2: Abemaciclib plus Fulvestrant in hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy. Oncologist. 2020;25(2):e243–51. https://doi.org/10.1634/theoncologist.2019-0551.
Article
CAS
PubMed
Google Scholar
Kluetz PG, Chingos DT, Basch EM, Mitchell SA. Patient-reported outcomes in cancer clinical trials: measuring symptomatic adverse events with the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Am Soc Clin Oncol Educ Book. 2016;35:67–73. https://doi.org/10.14694/EDBK_159514.
Article
PubMed
Google Scholar
Chang EM, Gillespie EF, Shaverdian N. Truthfulness in patient-reported outcomes: factors affecting patients’ responses and impact on data quality. Patient Relat Outcome Meas. 2019;10:171–86.
Article
PubMed
PubMed Central
Google Scholar